Sphinganine 1-phosphate is an intermediate in the sphingolipid metabolic pathway and is structurally similar to sphingosine. It has a protective effect on the kidney and liver through activation of the S1P1 receptor in mice. D-erythro-Dihydrosphingosine 1-phosphate acts as an agonist for S1P4 in Homo sapiens and may activate GPR63 (G protein-coupled receptor), mainly used in the study of Fabry disease, Gaucher disease, Krabbe disease and Leukodystrophy.

Sphinganine 1-phosphate (S1P) (1 μM) phosphorylates ERK MAPK, AKT and HSP27 and induces HSP27 in human renal endothelial cells. [2]

Methods: Male C57BL/6 mice were treated with Sphinganine 1-phosphate (0.1 mg/kg, 0.1 mg/kg intravenously immediately before reperfusion, 0.2 mg/kg subcutaneously 2 hours after reperfusion) and the changes in plasma levels of alanine aminotransferase (ALT) and creatinine (CR) were analyzed.
Results: The plasma levels of alanine aminotransferase (ALT) and creatinine (CR) were 80±6 U/L and 0.46±0.05 mg/dl, respectively; in mice treated with Sphinganine 1-phosphate (0.1 mg/kg), the increase in ALT (7474±557 U/L) and Cr (0.55±0.05 mg/dL) was significantly suppressed after 24 hours. [2]